Ash2014: anti-CD38 monoclonal antibody will be used to treat multiple myeloma

Source: on December 17, 2014, at the 56th Annual Meeting of the American Society of Hematology (ash), Dr Thomas Martin from the University of California, San Francisco, said that anti-CD38 mAb could be used as a new drug for standard treatment of multiple myeloma The drug can bind to myeloma cells expressing CD38, which can cause the immune cells to attack the tumor cells in vivo At the meeting, Dr Thomas Martin presented early trial data of anti-CD38 sar650984 monoclonal antibody (developed by Sanofi Oncology) combined with lenalidomide and dexamethasone in the treatment of recurrent / refractory multiple myeloma The response rate of the combined drug in phase IB test was 58% The progression free survival time was 6.2 months On the whole, there were 15 cases of progression free survival events, including 1 case of death unrelated to treatment and 14 cases of progression The median follow-up was 6 months It is worth mentioning that the overall response rate of combined drugs in patients with relapse / refractory of recent use of lenalidomide is 62.5% Dr Martin believes that anti-CD38 mAb will make a great contribution to the treatment of multiple myeloma, and the emergence of the drug will cause a sensation Another clinician, Dr Brad Kahl, said it was early However, Dr Martin said that in the context of multiple myeloma relapse / refractory, the current move is a significant improvement Immunotherapy drugs for inflammatory diseases (thalidomide, lenalidomide, pomadolamine) and proteasome inhibitors (bortezomib and kafezomib) increased the survival of patients from 3 to 7-10 years However, with the increase of recurrent / refractory patients, the average survival was only 9 months In addition, at the meeting, Dr Martin also mentioned the specific mode, dose and course of treatment of sar650984 combined with lenalidomide and dexamethasone in phase IB trial conducted by Sanofi The combination is well tolerated and the most common adverse reactions in the treatment include fatigue, nausea, upper respiratory tract infection and diarrhea.